Skip to main content
    M

    MaxCyte Inc (MXCT)

    Official site

    HEALTHCARE • MEDICAL DEVICES • NASDAQ

    $1.17
    -0.01 (-0.85%)

    Market Cap: $122.87M

    Last updated: Nov 17, 2026 at 4:15 PM ET

    MaxCyte Inc (MXCT) Statistics

    Updated Nov 17, 2026. Figures from company filings and market prices; estimates from consensus analysts.

    MaxCyte (MXCT) has a market cap of $122.87M and an enterprise value of $109.50M. It kept -81.40% of revenue as net income over the last 12 months. Its share count is down 2.88% from a year earlier.

    Total Valuation

    Enterprise value is 10.88% below the market cap, as cash exceeds debt.

    Market Cap$122.87M
    Enterprise Value$109.50M
    Latest price (Nov 17, 2026)$1.17

    Key Dates

    The next earnings report is expected on Mar 12, 2027, covering the quarter ending Dec 31, 2026.

    Next Earnings DateMar 12, 2027 (expected)
    Last Earnings DateNov 10, 2026
    Fiscal Year EndDecember

    Share Statistics

    The share count fell 3.07% in the quarter ended Sep 30, 2026 and shrank 0.75% a year over 2 years.

    Shares Outstanding103.54M
    Shares Change (YoY)-2.88%
    Shares Change (QoQ)-3.07%
    Share Count Growth (2Y CAGR)-0.75%

    Valuation Ratios

    Sales and book value multiples are 3.5x and 0.8x. Its year-end P/S ranged from 4.3x to 27.5x from 2020 to 2025.

    P/S Ratio3.5x
    Forward P/S3.5x
    P/B Ratio0.8x
    P/TBV Ratio0.8x

    Valuation history and multiples

    Price Statistics

    The stock is down 25.95% over 52 weeks and trades 6.40% below its 50-day average.

    Beta (1Y)1.43
    52-Week Change-25.95%
    1-Month Change-10.00%
    3-Month Change-15.83%
    6-Month Change+12.50%
    5-Year Change-85.85%
    Total Return (1Y)-25.95%
    Total Return (3Y CAGR)-34.42%
    Total Return (5Y CAGR)-37.61%
    Return vs SPY (1Y)-43.14%
    Max Drawdown (1Y)-61.58%
    Max Drawdown (3Y)-87.42%
    Sharpe Ratio (1Y)-0.53
    Correlation with SPY (1Y)0.28
    50-Day Average$1.25
    200-Day Average$1.07
    52-Week Range$0.64 to $1.80
    RSI (14 Days)42.0
    Average Volume (20 Days)1.47M

    The 5-year change compares month-end closes, adjusted for splits, through Oct 2026.

    Price chart

    Financial Position

    Current assets cover 7.83x current liabilities, and total debt is 0.00x shareholder equity.

    Current Ratio7.83x
    Quick Ratio7.37x
    Debt / Equity0.00x

    Returns and Efficiency

    Return on equity is -18.54% over the last 12 months, against a 5-year average of -15.76%.

    Return on Equity (ROE)-18.54%
    Return on Assets (ROA)-15.33%
    ROE (5Y Average)-15.76%
    ROA (5Y Average)-13.65%
    ROIC (5Y Average)-23.91%
    Asset Turnover0.17x
    Inventory Turnover0.86x
    Receivables Turnover4.30x
    Cash Conversion Cycle431 days

    Scores

    MXCT has an Altman Z-Score of 0.45, in the distress zone below 1.81, and a Piotroski F-Score of 2 of 9, in the weak band of 0 to 2.

    Altman Z-Score0.45
    Altman Z ZoneDistress
    Piotroski F-Score2 of 9
    Piotroski StrengthWeak

    Income Statement

    Revenue of $34.37M over the last 12 months is down 0.13% from the 12 months before.

    Revenue$34.37M
    Revenue Growth (YoY)-0.13%
    Gross Profit$27.84M
    Operating Income-$33.68M
    Pretax Income-$27.98M
    Net Income-$27.98M
    Reported EPS (TTM)-$0.23

    Trailing 12 months through Sep 30, 2026.

    Full financial statements

    Balance Sheet

    Shareholder equity funds 82.71% of the $182.48M in total assets.

    Cash and Equivalents$13.37M
    Total Debt$0
    Net Cash$13.37M
    Net Cash Per Share$0.13
    Working Capital$108.75M
    Shareholder Equity$150.93M
    Book Value Per Share$1.46
    Tangible Book Value$150.18M
    Tangible Book Per Share$1.45
    Total Assets$182.48M
    Total Liabilities$31.55M

    Balance sheet as of Sep 30, 2026.

    Full balance sheet

    Cash Flow

    After $424.00K of capital spending, operating cash flow left -$21.45M of free cash flow.

    Operating Cash Flow-$21.02M
    Capital Expenditures$424.00K
    Free Cash Flow-$21.45M
    FCF Per Share-$0.21
    Depreciation and Amortization$4.78M

    Trailing 12 months through Sep 30, 2026.

    Full cash flow statement

    Margins

    The operating margin is -97.99%.

    Gross Margin80.98%
    Operating Margin-97.99%
    Pretax Margin-81.40%
    Net Margin-81.40%
    FCF Margin-62.40%
    Gross Margin (5Y Average)85.80%
    Net Margin (5Y Average)-88.57%

    Growth

    Revenue fell 9.30% a year over 3 years.

    Revenue Growth (3Y CAGR)-9.30%
    Revenue Growth (5Y CAGR)+4.76%
    Book Value Per Share Growth (2Y CAGR)-15.16%
    Tangible Book Per Share Growth (2Y CAGR)-15.32%

    Revenue and profit by year

    Dividends and Yields

    MXCT does not pay a dividend. Its free cash flow yield is -17.71%.

    FCF Yield-17.71%
    Buyback Yield3.25%
    Shareholder Yield3.25%

    Peer Position

    Against 12 similar companies, MXCT has the 3rd highest P/S.

    P/S Ratio3.5x vs 2.1x median
    Revenue Growth (Trailing 4 Quarters, YoY)-0.13% vs +14.75% median

    Competitors compared

    Analyst Forecast

    Consensus estimates put revenue growth at 15.00% a year over the next 2 fiscal years.

    Revenue Growth Forecast (2Y CAGR)+15.00%

    Analyst estimates by year

    Price Target

    Analyst price targets are part of paid GNG plans. See plans

    GNG Valuation

    GNG viewUndervalued

    GNG fair value is part of GNG Pro. See plans

    Frequently Asked Questions About MXCT

    What is MXCT's market cap?

    MaxCyte has a market cap of $122.87M. Its enterprise value, which adds debt and subtracts cash, is $109.50M.

    How many shares of MXCT are outstanding?

    MaxCyte has 103.54M shares outstanding. The count is down 2.88% from a year earlier.

    Does MXCT pay a dividend?

    No. MaxCyte does not pay a dividend.

    How much debt does MXCT have?

    MaxCyte has $0 of total debt and $13.37M of cash and equivalents, a net cash position of $13.37M.